77
Participants
Start Date
June 30, 2021
Primary Completion Date
November 11, 2022
Study Completion Date
November 11, 2022
Orticumab
A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope
Placebo
Placebo for orticumab, containing all components of formulation except the active ingredient
Jacksonville Center for Clinical Research, Jacksonville
Dawes Fretzin Clinical Research Group, LLC, Indianapolis
SMS Clinical Research, Mesquite
Center for Clinical Studies, LTD.LLP, Webster
Texas Dermatology and Laser Specialists, San Antonio
CCT Research - Springville Dermatology, Springville
CCT- Research at the center for Dermatology and Plastic Surgery, Scottsdale
Vital Prospects Clinical Research Institute, PC, Tulsa
Las Vegas Clinical Trials, Las Vegas
Excel Clinical Research, Las Vegas
Derm Institute & Skin Care Ctr., Inc., Santa Monica
Blue Coast Research Center, Vista
Orange County Research Center, Tustin
Lead Sponsor
Abcentra
INDUSTRY